The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 November 2023) extended the licence of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old.
New threshold for CXCL13 concentration revolutionizes neuroborreliosis diagnosis
A newly defined threshold for the concentration of the cytokine CXCL13 may improve the diagnosis of neuroborreliosis.